InvestorsHub Logo
Followers 260
Posts 18292
Boards Moderated 0
Alias Born 01/19/2006

Re: Biobillionair post# 165519

Wednesday, 12/05/2018 10:22:58 PM

Wednesday, December 05, 2018 10:22:58 PM

Post# of 430271
NEJM, 12/06/2018, Toward Precision Policy—The Case of Cardiovascular Care, p. 2190.

Not particularly relevant, IMO. Does discuss a transition in hospital care: delivery of high value, better quality care rather than volume based care, resulting in lower costs. Skim revealed no specific reference to Amarin or Vascepa.; the thought of what Vascepa may accomplish is likely in forefront of Dr. Bhatt’s mind, IMO. Evolution to evidence-based health policy very similar to what I have heard from FDA’s Dr. Gottlieb
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News